Salarius Pharmaceuticals, Inc. (SLRX)
NASDAQ: SLRX · Real-Time Price · USD
1.370
-0.090 (-6.16%)
Nov 22, 2024, 4:00 PM EST - Market closed
Salarius Pharmaceuticals Employees
Salarius Pharmaceuticals had 2 employees as of December 31, 2023. The number of employees decreased by 10 or -83.33% compared to the previous year.
Employees
2
Change (1Y)
-10
Growth (1Y)
-83.33%
Revenue / Employee
n/a
Profits / Employee
-$2,496,820
Market Cap
1.97M
Employees Chart
Related Stocks
Company Name | Employees |
---|---|
Scorpius Holdings | 84 |
Sonnet BioTherapeutics Holdings | 12 |
Bluejay Diagnostics | 10 |
Phio Pharmaceuticals | 9 |
Shuttle Pharmaceuticals Holdings | 8 |
Aclarion | 6 |
GRI Bio | 4 |
IMAC Holdings | 4 |
SLRX News
- 5 months ago - Salarius Pharmaceuticals Announces 1-for-8 Reverse Stock Split - GlobeNewsWire
- 8 months ago - Salarius Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update - GlobeNewsWire
- 11 months ago - Investigator-initiated Phase 1/2 Clinical Trial Using Salarius Pharmaceuticals' Seclidemstat in Combination with Azacitidine to Treat Hematologic Cancers Resumes Patient Enrollment - GlobeNewsWire
- 1 year ago - Salarius Completes FDA Type B Meeting for Seclidemstat Ewing Sarcoma Development Program - GlobeNewsWire
- 1 year ago - Salarius Pharmaceuticals Reports Second Quarter 2023 Financial Results and Provides a Business Update - GlobeNewsWire
- 1 year ago - Salarius Pharmaceuticals Receives FDA Clearance of SP-3164 Investigational New Drug Application to Begin a Phase 1 Clinical Trial in Relapsed/Refractory Non-Hodgkin Lymphoma Patients - GlobeNewsWire
- 1 year ago - Salarius Pharmaceuticals Presents SP-3164 Targeted Protein Degrader Preclinical Data at the European Hematology Association 2023 Hybrid Congress - GlobeNewsWire
- 1 year ago - Salarius Pharmaceuticals Announces Closing of $6 Million Private Placement Priced At-the-Market Under Nasdaq Rules - GlobeNewsWire